Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-arm, Open-label, Phase 1 Trial to Evaluate the Safety and Tolerability, Pharmacokinetics and Anti-tumour Activity of MST-0312 When Given Alone and in Combination With Anticancer Treatments in Subjects With Solid Malignancies

NCT07610941 is registered in ClinicalTrials.gov with Mestag Therapeutics Limited as lead sponsor.

NCT NCT07610941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07610941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-arm, Open-label, Phase 1 Trial to Evaluate the Safety and Tolerability, Pharmacokinetics and Anti-tumour Activity of MST-0312 When Given Alone and in Combination With Anticancer Treatments in Subjects With Solid Malignancies
Lead sponsor
Mestag Therapeutics Limited
Phase
Phase 1
Overall status
Recruiting
Start date
April 9, 2026
Completion date
December 31, 2029
Enrollment
157 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer-neoplasms